CA3112205A1 - Process for making calcium alpha-ketoglutarate - Google Patents

Process for making calcium alpha-ketoglutarate Download PDF

Info

Publication number
CA3112205A1
CA3112205A1 CA3112205A CA3112205A CA3112205A1 CA 3112205 A1 CA3112205 A1 CA 3112205A1 CA 3112205 A CA3112205 A CA 3112205A CA 3112205 A CA3112205 A CA 3112205A CA 3112205 A1 CA3112205 A1 CA 3112205A1
Authority
CA
Canada
Prior art keywords
alpha
ketoglutaric acid
water
ketoglutarate
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3112205A
Other languages
English (en)
French (fr)
Inventor
David Eugene Pereira
Keshav Deo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ponce De Leon Health Designated Activity Co
Original Assignee
Ponce De Leon Health Designated Activity Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ponce De Leon Health Designated Activity Co filed Critical Ponce De Leon Health Designated Activity Co
Publication of CA3112205A1 publication Critical patent/CA3112205A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/418—Preparation of metal complexes containing carboxylic acid moieties
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/347—Saturated compounds containing more than one carboxyl group containing keto groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Fodder In General (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA3112205A 2018-09-25 2019-09-23 Process for making calcium alpha-ketoglutarate Pending CA3112205A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862736320P 2018-09-25 2018-09-25
US62/736,320 2018-09-25
PCT/US2019/052498 WO2020068705A1 (en) 2018-09-25 2019-09-23 Process of making calcium alpha-ketoglutarate

Publications (1)

Publication Number Publication Date
CA3112205A1 true CA3112205A1 (en) 2020-04-02

Family

ID=69952136

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3112205A Pending CA3112205A1 (en) 2018-09-25 2019-09-23 Process for making calcium alpha-ketoglutarate

Country Status (18)

Country Link
US (1) US11802103B2 (https=)
EP (1) EP3856166A4 (https=)
JP (1) JP7499259B2 (https=)
KR (1) KR102833111B1 (https=)
CN (1) CN112955139B (https=)
AU (1) AU2019350699B2 (https=)
BR (1) BR112021005668A2 (https=)
CA (1) CA3112205A1 (https=)
CL (1) CL2021000728A1 (https=)
CO (1) CO2021004529A2 (https=)
IL (1) IL281761B2 (https=)
MX (1) MX2021003482A (https=)
MY (1) MY203278A (https=)
PE (1) PE20211816A1 (https=)
PH (1) PH12021550403A1 (https=)
SG (1) SG11202102204PA (https=)
TW (1) TWI863930B (https=)
WO (1) WO2020068705A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7499259B2 (ja) 2018-09-25 2024-06-13 ポンス デ レオン ヘルス デジグネイテッド アクティビティ カンパニー αケトグルタル酸カルシウムを製造するためのプロセス
CN112941116B (zh) * 2021-01-04 2022-12-02 上海朴颐化学科技有限公司 一种酶法制备α-酮戊二酸钙的方法
CN114105761B (zh) * 2021-11-19 2024-06-21 广东派特埃尔生物科技有限公司 一种α-酮戊二酸钠盐的合成工艺
CN115974679A (zh) * 2022-12-20 2023-04-18 绍兴市精益生物化工有限公司 α-酮戊二酸钙盐制备方法
CN119977789A (zh) * 2025-02-12 2025-05-13 江苏惠利生物科技有限公司 一种离子交换树脂制备高纯度α-酮戊二酸钙的方法

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2776926A (en) 1955-08-04 1957-01-08 Eugene S Sharpe Preparation of alpha-ketoglutaric acid by serratia marcescens
US2917528A (en) 1956-08-24 1959-12-15 Victor Chemical Works Alkanolaminealkanephosphonic acids and salts thereof
US2841616A (en) * 1956-10-30 1958-07-01 Campbell Soup Co Process for the recovery of alpha-ketoglutaric acid
US3875304A (en) 1970-04-24 1975-04-01 Schlitz Brewing Co J Livestock feed composition and method of preparing the same
US4045585A (en) 1976-05-19 1977-08-30 Decel Corporation Flavored animal food compositions
DE3151196A1 (de) * 1981-12-23 1983-06-30 Kurt Heinz Prof. Dr. 7800 Freiburg Bauer Verfahren zur herstellung von gut loeslichen 5-aminosalicylsaeure-arzneimittelzubereitungen
US6451341B1 (en) 1990-02-05 2002-09-17 Thomas J. Slaga Time release formulation of vitamins, minerals and other beneficial supplements
US5646187A (en) 1992-05-20 1997-07-08 Ab Erik Vinnars Use of alpha-ketoglutarate
US6306430B1 (en) 1998-04-16 2001-10-23 The Iams Company Process for decreasing adiposity using vitamin a as a dietary supplement
US6905707B2 (en) 1998-05-28 2005-06-14 Medical Research Institute Controlled release arginine alpha ketoglutarate
CO5140079A1 (es) 1998-10-14 2002-03-22 Novartis Ag Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo
US6649654B1 (en) 1999-11-23 2003-11-18 The Regents Of The University Of California Methods for identifying and using IKK inhibitors
US7169755B2 (en) 2000-12-20 2007-01-30 Alcon, Inc. Solution for removing cataracts via liquefracture
EP1622629B1 (en) * 2003-05-07 2013-07-10 Osteologix A/S Controlled-release composition containing a strontium salt
EP1744770A2 (en) * 2004-05-06 2007-01-24 Osteologix A/S High yield and rapid syntheses methods for producing metallo-organic salts
PL368572A1 (en) * 2004-06-17 2005-12-27 Sgp & Sons Ab Pharmaceutical compound for prevention and therapy of increased level of cholesterol, ldl and triglycerides as well as application of the pharmaceutical compound as an agent acting against atherosclerosis and used in circulatory system affections
US20090005437A1 (en) 2004-08-09 2009-01-01 Eyal Gottlieb Alpha-Ketoglutarates and Their Use as Therapeutic Agents
ES2510690T3 (es) 2004-12-17 2014-10-21 Alan B. Cash Método para extender la esperanza de vida y retrasar la aparición de enfermedad relacionada con la edad
US20060234250A1 (en) 2005-04-15 2006-10-19 Powers Ralph W Iii Methods of screening and compositions for life span modulators
WO2007001883A2 (en) 2005-06-20 2007-01-04 Accera, Inc. Method to reduce oxidative damage and improve mitochondrial efficiency
US20070105942A1 (en) 2005-11-08 2007-05-10 Heuer Marvin A Supplemental dietary composition for turning on anabolic switches in muscle, stimulating and/or optimizing protein synthesis, and/or potently signaling muscle building and/or growth via molecular pathways
US8367121B2 (en) 2005-11-23 2013-02-05 Florida A & M University Nutraceutical agent for attenuating the neurodegenerative process associated with Parkinson's disease
PL379512A1 (pl) 2006-04-21 2007-10-29 Sgp & Sons Ab Nowe metody i ich zastosowanie
PL226695B1 (pl) 2006-07-03 2017-08-31 Danuta Kruszewska Środek do zastosowania w zapobieganiu i/lub hamowaniu kolonizacji Helicobacter pylori, zastosowanie soli kwasu alfa‑ketoglutarowego z metalami alkalicznymi i ziem alkalicznych do wytwarzania środka leczniczego oraz dodatku do żywności do zapobiegania i/lub hamowania kolonizacji Helicobacter pylori
NZ579340A (en) 2007-03-19 2012-05-25 Metaproteomics Llc Methods and compositions for promoting bone and joint health comprising berberine
EP2173336B1 (en) 2007-07-02 2016-03-30 Protista Biotechnology AB Alpha-ketoglutaric acid for use in the treatment of hypertension or pulmonary hypertension
EP2033623A1 (en) 2007-09-07 2009-03-11 Cutech S.R.L. Compositions comprising ornithine ketoglutarate (OKG)
JP5406643B2 (ja) * 2008-09-22 2014-02-05 日本合成化学工業株式会社 α−オキソカルボン酸の金属塩の製造方法
CN101759553A (zh) 2008-11-21 2010-06-30 扬子江药业集团北京海燕药业有限公司 α-酮酸钙的制备方法
DE102009016119A1 (de) 2009-04-03 2010-10-14 Evonik Degussa Gmbh Nahrungsergänzungsmittel enthaltend alpha-Ketosäuren zur Unterstützung der Diabetestherapie
AU2010233073B2 (en) 2009-04-10 2014-07-31 Haiyan Qi Novel anti-aging agents and methods to identify them
AU2010247800A1 (en) 2009-05-11 2011-12-15 Berg Llc Methods for the diagnosis of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
JP2012527894A (ja) 2009-05-28 2012-11-12 ザ・アイムス・カンパニー 被覆キブル形態のペットフード
AU2010258356B2 (en) 2009-06-12 2017-01-19 Generex Pharmaceuticals, Inc. Compositions and methods for prevention and treatment of brain diseases and conditions
WO2011000218A1 (en) 2009-06-30 2011-01-06 Shuen-Lu Huang Compositions containing berberine or analogs thereof for treating rosacea or red face related skin disorders
WO2011060305A1 (en) 2009-11-12 2011-05-19 Nox Technologies, Inc. Potato skin compositions that lower cytosolic nadh level to mimic calorie restriction
WO2012114204A2 (en) 2011-02-15 2012-08-30 Ecole Polytechnique Federale De Lausanne (Epfl) Epfl-Tto Methods of treating mitochondrial dysfunction
CN103491804A (zh) 2011-04-18 2014-01-01 雀巢产品技术援助有限公司 具有α-HICA 和二十碳五烯酸的营养组合物
US9248185B2 (en) 2011-06-16 2016-02-02 President And Fellows Of Harvard College Methods of increasing satellite cell proliferation
CN102586347B (zh) * 2012-03-06 2014-04-09 江南大学 一种两阶段pH控制高产a-酮戊二酸的方法
US9532997B2 (en) 2012-04-03 2017-01-03 Whitehead Institute For Biomedical Research Compositions and methods for promoting intestinal stem cell function
ITBO20120226A1 (it) 2012-04-24 2013-10-25 Alfa Wassermann Spa Composizioni comprendenti ornitina alfa-chetoglutarato, processi per il loro ottenimento e il loro uso.
JP6029058B2 (ja) * 2012-09-14 2016-11-24 国立研究開発法人農業・食品産業技術総合研究機構 シュウ酸カルシウムを含む氷核活性剤
FI3398594T3 (en) 2012-09-19 2024-09-23 Grespo Ab Compositions for improvement of brain function
CN102976927A (zh) * 2012-12-26 2013-03-20 天津天成制药有限公司 α-酮戊二酸钙的制备方法
CA2896646A1 (en) 2012-12-27 2014-07-03 Hayashibara Co., Ltd. Skin-exterior anti-ageing composition and production method therefor
WO2014116985A1 (en) 2013-01-25 2014-07-31 Winning The Fight Inc. Composition for treatment of neurodegenerative disease
US9511057B2 (en) 2013-03-15 2016-12-06 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating denervation-induced muscle atrophy
CA2902603C (en) 2013-03-19 2021-03-02 University Of South Florida Compositions and methods for producing elevated and sustained ketosis
US20160263092A1 (en) 2013-12-19 2016-09-15 Twi Biotechnology, Inc. Therapeutic uses of berberine formulations
CN106163513A (zh) 2014-02-12 2016-11-23 加利福尼亚大学董事会 用于治疗衰老和与年龄相关的疾病和症状的组合物和方法
WO2015171723A1 (en) 2014-05-06 2015-11-12 Research Development Foundation Methods for treating insulin resistance and for sensitizing patients to glp1 agonist therapy
CA2953387C (en) 2014-06-30 2023-11-28 The Regents Of The University Of California Ketobutyrate compounds and compositions for treating age-related symptoms and diseases
CA2945609C (en) 2014-07-29 2023-05-23 Shenzhen Hightide Biopharmaceutical, Ltd. Berberine-ursodeoxycholic salt, method of preparation and application therof
US20170266253A1 (en) 2014-07-31 2017-09-21 Indiana University Research And Technology Corporation Antithetical regulation of endothelial ace and ace2 by brg1-foxm1 complex underlies pathological cardiac hypertrophy
CN104529755B (zh) * 2014-12-29 2016-01-06 精晶药业股份有限公司 一种从转化液中分离α-酮戊二酸的方法
CA2981754A1 (en) 2015-04-06 2016-10-13 Shenzhen Hightide Biopharmaceutical, Ltd. Conjugate compounds of ursodeoxycholic, berberine or l-carnitine, and compositions and methods thereof
JP2018517774A (ja) 2015-06-10 2018-07-05 エリジウム・ヘルス・インコーポレイテッド ニコチンアミドリボシドおよびプテロスチルベン組成物ならびに皮膚障害の処置のための方法
WO2017008060A1 (en) 2015-07-08 2017-01-12 Unity Biotechnology, Inc. Compositions and methods for treating senescence-associated diseases and disorders
US20190247342A1 (en) 2016-09-30 2019-08-15 The Regents Of The University Of California Alpha-Ketobutyrate, 2-Hydroxybutyrate, and Alpha-Ketoglutarate for Stimulating Hair Growth
PL231635B1 (pl) * 2017-01-03 2019-03-29 Politechnika Poznanska Sposób produkcji kwasu alfa-ketoglutarowego (AKG) z jednoskładnikowych roztworów wodnych
MX2017004010A (es) 2017-03-27 2018-02-09 Antonio Hernandez Miramontes Jorge Mezcla de oxalacetato, alfacetoglutarato, ácido tartánico y sales de lactato de calcio y sodio, para tratar pacientes con insuficiencia renal crónica.
EP3615029A4 (en) 2017-04-25 2021-04-21 Buck Institute for Research on Aging FORMULATIONS TO EXTEND LIFE AND HEALTH
US20200253907A1 (en) 2017-08-21 2020-08-13 The Regents Of The University Of California Compositions and Methods for Treating Neurodegenerative Diseases
JP7499259B2 (ja) 2018-09-25 2024-06-13 ポンス デ レオン ヘルス デジグネイテッド アクティビティ カンパニー αケトグルタル酸カルシウムを製造するためのプロセス
WO2020086733A1 (en) 2018-10-24 2020-04-30 Ponce De Leon Health Designated Activity Company Nicotinamide riboside compositions for healthspan extension
JP2022536653A (ja) 2019-06-10 2022-08-18 バック インスティチュート フォー リサーチ オン エージング 老化関連分泌表現型を修整する方法および組成物
DK3980001T3 (da) * 2019-06-10 2025-12-01 Ponce De Leon Health Designated Activity Company Depotsammensætninger af alfa-ketoglutarat
CA3188646A1 (en) 2020-07-02 2022-01-06 Ponce De Leon Health Designated Activity Company Compositions and methods for treating crp-mediated diseases
CN112941116B (zh) * 2021-01-04 2022-12-02 上海朴颐化学科技有限公司 一种酶法制备α-酮戊二酸钙的方法
CN115974679A (zh) * 2022-12-20 2023-04-18 绍兴市精益生物化工有限公司 α-酮戊二酸钙盐制备方法

Also Published As

Publication number Publication date
US11802103B2 (en) 2023-10-31
US20210371368A1 (en) 2021-12-02
KR102833111B1 (ko) 2025-07-10
JP7499259B2 (ja) 2024-06-13
IL281761B1 (en) 2025-05-01
PE20211816A1 (es) 2021-09-14
CO2021004529A2 (es) 2021-04-30
TWI863930B (zh) 2024-12-01
SG11202102204PA (en) 2021-04-29
WO2020068705A1 (en) 2020-04-02
JP2022502489A (ja) 2022-01-11
CN112955139B (zh) 2025-04-18
EP3856166A1 (en) 2021-08-04
KR20210065120A (ko) 2021-06-03
EP3856166A4 (en) 2022-06-22
MY203278A (en) 2024-06-21
PH12021550403A1 (en) 2021-10-04
CL2021000728A1 (es) 2021-10-22
BR112021005668A2 (pt) 2021-06-22
MX2021003482A (es) 2021-06-18
TW202024013A (zh) 2020-07-01
IL281761A (en) 2021-05-31
AU2019350699B2 (en) 2024-05-23
AU2019350699A1 (en) 2021-04-08
IL281761B2 (en) 2025-09-01
CN112955139A (zh) 2021-06-11

Similar Documents

Publication Publication Date Title
AU2019350699B2 (en) Process of making calcium alpha-ketoglutarate
Tager et al. 2-Aminonorbornane-2-carboxylic acid. Preparation, properties, and identification of the four isomers
JP3090960B2 (ja) クレアチン―ピルベート及びその製造方法
Wittle et al. Oxidative Degradation of Vitamin Bc (Pteroylglutamic Acid1)
Beyerman et al. Stereospecific synthesis and optical resolution of 5‐hydroxypipecolic acid
JP6974788B2 (ja) イミダゾピロロキノリン塩及びその製造方法、並びに、医薬品、化粧品及び食品
Bates et al. Structures of eurycomalactone and related terpenoids
HK40053335A (en) Process of making calcium alpha-ketoglutarate
HK40053335B (zh) 用於制备α-酮戊二酸钙的方法
JPH03279348A (ja) ２，４，５―トリフルオロ―３―アルコキシ安息香酸の製造方法
EP0064286A2 (en) New derivatives of alkanediols having hypolipidaemic activity, methods for their preparation and pharmaceutical compositions containing them
JP2000510486A (ja) α−トコフェロール−４−アミノ安息香酸エステル化合物及びその製造方法
US5011974A (en) Process for the preparation of derivative of 2-diethylamino-1-methylethyl-1-hydroxy-(bicyclohexyl)-2-carboxylate
CH695217A5 (de) Verfahren zur Trennung optischer Isomeren von Tetrahydrofolsäureestersalzen und Tetrahydrofolsäure.
KR910003184B1 (ko) 프롤린 유도체의 제조방법
JPH03145492A (ja) ピロロキノリンキノンエステル
RU1806134C (ru) Трис-/2-оксиэтил/аммониева соль 3,4-дихлорфенилсульфонилуксусной кислоты в качестве стимул тора корнеобразовани
SU671270A1 (ru) Гидрохлорид 1,2 -диметил-транс-декагидрохинолин-4-спиро-2-тетрагидропиранона-4, про вл ющий противоаритмическую активность, и способ его получени
KR100461572B1 (ko) Ｌ-카르니틴 칼슘 염과 이의 제조방법
JPS62242653A (ja) ５−ヒドロキシノルバリン誘導体の製法
JPH03170486A (ja) 新規なオキサゾピロロキノリン化合物
JPH05170721A (ja) 芳香族アミド化合物および神経成長因子分泌誘導剤
JPS6125028B2 (https=)
JPH03170484A (ja) 新規なオキサゾピロロキノリン化合物
GB2051070A (en) N-(phosphonoacetyl)-L-aspartic Acid Compounds

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220927

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240806

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240920

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240920

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240920

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241224

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250225

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250225

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250922

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250922

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251203

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251209